type 1 and type 2 diabetes mellitus
Endocrinology · 2005–2007
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| insulin glulisine Treatment of Type 1 and Type 2 diabetes mellitus in adults and children older than 12 years who require insulin for the control of hyperglycaemia. | Mar 2007 | Recommended | no section in document |
| insulin glargine Treatment of type 1 and type 2 diabetes mellitus in adults and children (aged 6-15 years) who require insulin for control of hyperglycaemia. | Jul 2005 | Not recommended | no section in document |
What the PBS pays
$75M in government benefit over 2024–25, across 364,528 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| insulin glargine | $73.4M |
| Insulin Glulisine | $1.7M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.